In conclusion, we identify pacritinib as a strong inhibitor of squamous cell lung cancer glucose consumption that functions by inhibiting FLT3 and limiting Hexokinase 1 expression. The gene discussed is FLT3; the disease is squamous cell lung carcinoma.